Treatment of squamous cell carcinoma of the posterior pharyngeal wall: Radiotherapy versus surgery.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 26613802.
- Also identified by DOI 10.1002/hed.24307.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Treatment strategy in squamous cell carcinoma (SCC) of the posterior pharyngeal wall is still being debated. We performed a retrospective analysis according to delivered treatment. One hundred eighty patients were treated between 1997 and 2011. Eighty-nine patients (49.4%) received surgery +/- radiotherapy (RT), whereas 91 (50.6%) received definitive RT +/- chemoradiotherapy (RT/CRT). Five-year overall survival (OS) was 33.4%. There was a significant 5-year OS benefit in surgical treatment versus RT/CRT (43% vs 24.1%; p = .002). Multivariate analysis showed that current smokers, T3 to T4 classification, well-differentiated SCC, and nonsurgical treatment were associated with reduced OS. Subgroup analysis showed significant survival benefit of surgical treatment compared with RT/CRT in patients with T1 to T2 but not in T3 to T4 disease. Surgical management translated into a survival benefit, even in early T classification. These results should be interpreted with caution for selection bias. Surgery remains the standard of care in localized posterior pharyngeal wall SCC. Primary CRT should be considered for nonoperable disease. © 2015 Wiley Periodicals, Inc. Head Neck 38: E1722-E1729.
Medical subject headings
- Carcinoma, Squamous Cell
- Chemoradiotherapy
- Pharyngeal Neoplasms